I am asking mechanistically rather than practically — I want the model, not the protocol.
I want to know what the trade-off actually is rather than which option is fashionable.
I would rather have a defensible reason than a marginal improvement.
What does each option buy me, and what does it cost me?
Answer first: oral peptide delivery works by co-formulating an absorption enhancer that transiently raises local gastric pH and permeability, and the resulting bioavailability is low single-figure per cent at best.
Gastric residence time and gastric pH both vary with what else is in the stomach, which is the mechanistic reason the conditions are so specific.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
The relevant detail is that orforglipron is a non-peptide small-molecule GLP-1 receptor agonist. It has no absorption enhancer, no food and water restrictions of the same kind, and conventional oral pharmacokinetics.
The caveat is that the administration conditions are part of the dose. Ignoring them does not produce a smaller effect so much as an unpredictable one.
Do not compare oral and injectable milligrams. Compare exposures.
edited 1 Aug 2024 by orla_ferriter — removed a claim I could not source
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe honest answer is that the oral route costs a great deal of drug and buys convenience, and for some people that trade is obviously worth it.
Between-subject variability in exposure is high, and within-subject variability is high enough that adherence to the administration conditions matters more than it does for almost any other oral drug.
The underlying point is that dose-equivalence claims between oral and injectable forms of the same molecule should be read as exposure claims rather than milligram claims, because the milligrams are not comparable.
Orforglipron is being evaluated in the ATTAIN and ACHIEVE programmes, for obesity and type 2 diabetes respectively.
Bioavailability figures are population means around which individuals vary widely, and the variability is the clinically relevant part.
One per cent bioavailability explains the whole difference in tablet strength.
The short version: it works, the bioavailability is around one per cent, the variability is high, and the small-molecule agents are a different solution to the same problem.
The administration conditions are not optional: on waking, on an empty stomach, with no more than about half a glass of water, and nothing else by mouth for at least thirty minutes. Food or extra water dilutes the local pH effect and can substantially reduce absorption.
The part that matters: absolute bioavailability is on the order of one per cent, which is why the oral tablet strengths are an order of magnitude above the injectable milligram doses for a comparable exposure.
SNAC as a permeation enhancer has published pharmacokinetic characterisation showing the pH and permeability mechanism directly.
Research-use material in an oral formulation has no absorption enhancer, no dissolution specification and no meaningful exposure expectation.
Empty stomach, small water volume, wait thirty minutes. The conditions are the dose.
This is answerable precisely from the pharmacokinetic data, and the numbers are more interesting than the marketing.
Oral semaglutide is co-formulated with sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, usually written SNAC. It raises pH locally in the stomach, protecting the peptide from pepsin, and transiently increases transcellular permeability at the absorption site.
Nothing here is medical advice.
Oral peptide and oral small molecule are different technologies with different rules.
Answering this needs to know which agent, because oral semaglutide and orforglipron are chemically unrelated and share only a route.
A small molecule that activates a class B peptide receptor is a genuinely difficult chemistry problem, which is why this took as long as it did and why the binding site is unusual.
The PIONEER programme evaluated oral semaglutide in type 2 diabetes and is the appropriate citation for that agent.
The caveat is that mechanism explains and does not predict. A clean mechanistic story has repeatedly failed to survive a Phase 3 in metabolic medicine.
If convenience is the goal, this is the trade being made, and it is a defensible one.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.